EE200200531A - Production and use of therapeutic intracellular antibodies - Google Patents

Production and use of therapeutic intracellular antibodies

Info

Publication number
EE200200531A
EE200200531A EEP200200531A EEP200200531A EE200200531A EE 200200531 A EE200200531 A EE 200200531A EE P200200531 A EEP200200531 A EE P200200531A EE P200200531 A EEP200200531 A EE P200200531A EE 200200531 A EE200200531 A EE 200200531A
Authority
EE
Estonia
Prior art keywords
production
intracellular antibodies
therapeutic
therapeutic intracellular
antibodies
Prior art date
Application number
EEP200200531A
Other languages
Estonian (et)
Inventor
Valkna Andres
Kogerman Priit
Original Assignee
O� InBio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by O� InBio filed Critical O� InBio
Priority to EEP200200531A priority Critical patent/EE200200531A/en
Priority to AU2003266225A priority patent/AU2003266225A1/en
Priority to EP03797197A priority patent/EP1539823A1/en
Priority to CA002499321A priority patent/CA2499321A1/en
Priority to PCT/EE2003/000005 priority patent/WO2004026911A1/en
Priority to US10/528,073 priority patent/US20080063633A1/en
Publication of EE200200531A publication Critical patent/EE200200531A/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200531A 2002-09-17 2002-09-17 Production and use of therapeutic intracellular antibodies EE200200531A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EEP200200531A EE200200531A (en) 2002-09-17 2002-09-17 Production and use of therapeutic intracellular antibodies
AU2003266225A AU2003266225A1 (en) 2002-09-17 2003-09-16 Obtaining and use of therapeutic antibodies entering into the cell
EP03797197A EP1539823A1 (en) 2002-09-17 2003-09-16 Obtaining and use of therapeutic antibodies entering into the cell
CA002499321A CA2499321A1 (en) 2002-09-17 2003-09-16 Obtaining and use of therapeutic antibodies entering into the cell
PCT/EE2003/000005 WO2004026911A1 (en) 2002-09-17 2003-09-16 Obtaining and use of therapeutic antibodies entering into the cell
US10/528,073 US20080063633A1 (en) 2002-09-17 2003-09-16 Obtaining and Use of Therapeutic Antibodies Entering Into the Cell

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EEP200200531A EE200200531A (en) 2002-09-17 2002-09-17 Production and use of therapeutic intracellular antibodies

Publications (1)

Publication Number Publication Date
EE200200531A true EE200200531A (en) 2004-04-15

Family

ID=32010907

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200531A EE200200531A (en) 2002-09-17 2002-09-17 Production and use of therapeutic intracellular antibodies

Country Status (6)

Country Link
US (1) US20080063633A1 (en)
EP (1) EP1539823A1 (en)
AU (1) AU2003266225A1 (en)
CA (1) CA2499321A1 (en)
EE (1) EE200200531A (en)
WO (1) WO2004026911A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504585A (en) 2009-09-09 2013-02-07 セントローズ， エルエルシー Extracellular targeted drug complex
CA2867188A1 (en) * 2012-03-15 2013-09-19 Permeon Biologics, Inc. Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE251913T1 (en) * 1997-05-21 2003-11-15 Univ Leland Stanford Junior COMPOSITION AND METHOD FOR DELAYING TRANSPORT THROUGH BIOLOGICAL MEMBRANES
US6238876B1 (en) * 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
SE9902899D0 (en) * 1999-08-13 1999-08-13 Karolinska Innovations Ab New peptides, corresponding antibodies, and compositions thereof

Also Published As

Publication number Publication date
AU2003266225A1 (en) 2004-04-08
US20080063633A1 (en) 2008-03-13
EP1539823A1 (en) 2005-06-15
WO2004026911A1 (en) 2004-04-01
CA2499321A1 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
CY2016035I1 (en) THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
DK1572946T3 (en) Therapeutic human monoclonal anti-IL-1R1 antibody
CY2015015I1 (en) PRODUCTION OF THIACOMYCIN
IL209010A0 (en) Use of tnfalpha antibodies and another drug
NO20033387L (en) Modified antibodies and methods of use
DE60324099D1 (en) DRUG-CONTAINING TAMPON
EP1482984A4 (en) Surrogate antibodies and methods of preparation and use thereof
IS7725A (en) Imidazolopyridine and methods of manufacture and use
MA28802B1 (en) THERAPEUTIC USES OF RTP801 INHIBITORS
DK1537096T3 (en) Derivatives of dioxane-2-alkylcarbamates, their preparation and therapeutic use
NO20044916L (en) Preparations of sulfinylacetamide
EP1789027A4 (en) Therapeutic use of anti-tf-antigen antibody
DK1513835T3 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use
NO20050689L (en) Therapeutic use
IS6967A (en) New cyano-linked dihydropyrimidine compounds and their use in the treatment of diseases
HK1155670A1 (en) Therapeutic use of anti-cs1 antibodies
DE60238174D1 (en) Fluoropolymers and methods of preparation and use
EE200200531A (en) Production and use of therapeutic intracellular antibodies
NO20034172L (en) Bicyclic guanidine derivatives and therapeutic uses thereof
DE60316792D1 (en) PHARMACEUTICAL USE OF COX-2 INHIBITORS IN ANGIOGENESIS-MEDIATED EYES DISEASES
FI20020360A0 (en) New use of biologically active product
ITMI20041962A1 (en) "PEPTIDE OF ANGIOSTATIN AND ITS THERAPEUTIC EMPLOYEES"
DE60326437D1 (en) THERAPEUTIC USE OF SAPOGENINES
FR2872390B1 (en) OBJECT OF JEWELRY, ACCESSORIES AND WATCHMAKING
IS6234A (en) New pharmaceutical forms and methods of their preparation